Citius Pharmaceuticals Inc
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
CTXR$0.53-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| 3.1 | Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 18, 2014). |
| 3.2 | Certificate of Amendment to the Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc., effective September 16, 2016 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 21, 2016). |
| 3.3 | Certificate of Amendment to the Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc., effective June 9, 2017 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on June 8, 2017). |
| 3.4 | Certificate of Amendment to the Articles of Incorporation of Citius Pharmaceuticals Inc., dated June 21, 2021 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on June 22, 2021). |
| 3.5 | Certificate of Change filed with the Secretary of State of Nevada on November 22, 2024 (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 26, 2024). |
| 3.6 | Certificate of Designation of Series A Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on April 18,2025). |
| 3.7 | Amended and Restated Bylaws of Citius Pharmaceuticals, Inc.(incorporated by reference to Exhibit 3.1 to the Form 8-K filed on February 9, 2018). |
| 3.8 | Amendment to the Amended and Restated Bylaws of Citius Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 to the Form 8-K filed on April 18, 2025). |
| 4.1 | Form of Pre-funded Warrant issued on April 2, 2025 (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on April 2, 2025). |
| 4.2 | Form of Placement Agent Warrant issued on April 2, 2025 (incorporated by reference to Exhibit 4.2 to the Form 8-K filed on April 2, 2025). |
| 10.1 | Form of Securities Purchase Agreement, dated as of April 1, 2025, by and among Citius Pharmaceuticals, Inc. and the investor signatory thereto (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on April 2, 2025). |
| 10.2 | Subscription and Investment Representation Agreement, dated April 17, 2025, by and between Citius Pharmaceuticals, Inc. and Leonard Mazur (incorporated by reference to Exhibit 10.1 to the Form 8-K filed on April 18,2025). |
| 31.1 | Certification of the Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a).* |
| 31.2 | Certification of the Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a).* |
| 32.1 | Certification of the Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.* |
| EX-101.INS | Inline XBRL Instance Document* |
| EX-101.SCH | Inline XBRL Taxonomy Extension Schema Document* |
| EX-101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document* |
| EX-101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document* |
| EX-101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document* |
| EX-101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document* |
| EX-104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)* |
| * | Filed herewith. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.